Submit Deal

VARMX

HQ - Leiden

Summary

VarmX, a biotech company developing novel therapies for coagulation disorders, including treatments to bypass direct oral anticoagulants, particularly FXa inhibitors

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 86 M

Avg. Deal Size£ 86 M

Market Context

Senior Management

John Glasspool
Chief Executive Officer

Sort

16 Sep 2025|Netherlands|Biotechnology

Target: VARMX

Bidder: CSL LIMITED

6 Service Providers

4 Target | 2 Bidder

20 Dealmakers

2 Target | 18 Bidder

£ 86 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy